GlobalMed® Donates Telehealth Services and Software to States Impacted by Hurricane Helene

PHOENIX, Oct. 10, 2024 /PRNewswire/ — GlobalMed, the leader in telehealth and medical technology, has announced its commitment to support the states impacted by Hurricane Helene by donating vital telehealth services and software. The donations are earmarked for state entities and non-profit organizations involved in disaster recovery efforts.Continue reading

The Future of Biotech: Steve Potts on Innovation, Policy, and the Impact of the IRA

In this episode of the Vital Health podcast, host Duane Schulthess sits down with Steve Potts, a seasoned entrepreneur and CEO of SLAM BioTherapeutics. They dive deep into the challenges and opportunities in biotech, exploring how recent legislative changes, like the IRA, are reshaping the industry. Steve shares insights on the shift from small molecules to biologics, the funding landscape, and the critical role of American innovation in drug development. Tune in to hear about the state of biotech in the U.S., the future of drug discovery, and what it takes to succeed in this evolving field.Continue reading

Share you expertise – Volunteer to Judge Pitches at Venture Devils

At the ASU Venture Devils program, on Saturday, November 16th 2024, 70-90 top student ventures will be pitching for varying amounts of seed funding from various funding tracks associated with the Venture Devils program. This large-scale event is happening in-person at ASU SkySong in Scottsdale, AZ. Volunteer VIP Judges are needed to provide thoughtful and thorough evaluations of these teams. We are looking for diverse, interdisciplinary judging panels and for consistency with this across all judging rooms. These panels will be assembled based on the sign-up response in coordination with the judges and stakeholders that are participating. We will notify you if you’ve been selected as a judge at least one week prior to the event. Continue reading

Gilead Signs Royalty-Free Voluntary Licensing Agreements with Six Generic Manufacturers to Increase Access to Lenacapavir for HIV Prevention in High-Incidence, Resource-Limited Countries  

  • License for Companies to Manufacture and Supply High-Quality, Low-Cost Versions of Lenacapavir for 120 Primarily Low- and Lower-Middle Income Countries –
  • Gilead Plans to PriceProduct at No Profit to the Company and Supply Lenacapavir Until Generic Manufacturers Fully Support Demand –
  • Agreements Also Cover Lenacapavir for HIV Treatment in Heavily Treatment-Experienced Adults with Multi-Drug Resistant HIV –

Continue reading